

Research Article

Interferon- γ -Mediated Natural Killer Cell Activation by an Aqueous *Panax ginseng* Extract

Kazuyoshi Takeda^{1,2} and Ko Okumura^{2,3,4}

¹Division of Cell Biology, Biomedical Research Center, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan

²Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan

³Atopy (Allergy) Research Center, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan

⁴Department of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan

Correspondence should be addressed to Kazuyoshi Takeda; ktakeda@juntendo.ac.jp

Received 31 July 2015; Revised 20 October 2015; Accepted 26 October 2015

Academic Editor: Nunziatina De Tommasi

Copyright © 2015 K. Takeda and K. Okumura. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Panax ginseng extracts are used in traditional herbal medicines, particularly in eastern Asia, but their effect on natural killer (NK) cell activity is not completely understood. This study aimed to examine the effects of *P. ginseng* extracts on the cytotoxic activity of NK cells. We orally administered *P. ginseng* extracts or ginsenosides to wild-type (WT) C57BL/6 (B6) and BALB/c mice and to B6 mice deficient in either recombination activating gene 2 (RAG-2) or interferon- γ (IFN- γ). We then tested the cytotoxic activity of NK cells (of spleen and liver mononuclear cells) against NK-sensitive YAC-1 cells. Oral administration of *P. ginseng* aqueous extract augmented the cytotoxicity of NK cells in WT B6 and BALB/c mice and in RAG-2-deficient B6 mice, but not in IFN- γ -deficient B6 mice. This effect was only observed with the aqueous extract of *P. ginseng*. Interestingly, the ginsenosides Rb1 and Rg1 did not augment NK cell cytotoxicity. These results demonstrated that the aqueous *P. ginseng* extract augmented NK cell activation *in vivo* via an IFN- γ -dependent pathway.

1. Introduction

Panax ginseng (*P. ginseng*) roots provide a health food and are used to prepare a range of remedies employed in traditional Asian medicine. *P. ginseng* has been reported to possess several biological activities including antiaging, antidiabetic, anticarcinogenic, analgesic, antipyretic, antistress, antifatigue, and tranquilizing effects [1–3]. Ginsenosides, saponin molecules that are unique to *Panax* species, are generally considered to be the primary active pharmacological components of *P. ginseng* [4]. These compounds are also used as markers for the quality control and standardization of commercially available extracts of *Panax* species. In twenty different saponins, the ginsenosides, Rb1, Rg1, and Rd1, and the notoginsenoside, R1, are considered to be the major bioactive components [5]. In addition, nonsaponin compounds present in *P. ginseng* are also reported to have hypoglycemic [6] and antitumor activities [7].

There are a number of reports concerning the immunological effects of *P. ginseng*. However, it is unclear whether *P. ginseng* activates or suppresses immune responses. Some reports have shown that *P. ginseng* augments the activity of natural killer (NK) cells [8–13], which play an important role in innate immunity against infection and tumor development [14, 15]. However, the mechanisms involved in this augmentation of NK cell activity have not been identified. The present study examined the effects of *P. ginseng* on NK cell cytotoxicity using gene-targeted mice. We demonstrated that an aqueous extract of *P. ginseng* augmented the cytotoxicity of NK cell depending on interferon- γ (IFN- γ).

2. Materials and Methods

2.1. Mice. All mouse experiments were approved by Animal Care and Use Committee in Juntendo University (number 25008 on 2013/2/14 and number 260012 on 2014/2/7).

Wild-type (WT) male C57BL/6 (B6) and BALB/c mice were purchased from Charles River Japan Inc. (Yokohama, Japan) at 6 weeks of age. IFN- γ deficient (IFN- $\gamma^{-/-}$) and recombination activating gene 2- (RAG-2-) deficient (RAG-2 $^{-/-}$) B6 mice were derived as described previously [16, 17]. All mice were maintained under specific pathogen-free conditions and used in accordance with the institutional guidelines of Juntendo University.

2.2. Reagents. Aqueous (batch number 67EX0326) and ethanol (50% [batch number 67-X-282] or 95% [batch number 67-X-281]) extracts of *P. ginseng* were provided by Nagaoka & Co., Ltd. (Nishinomiya, Hyogo, Japan). Briefly, the aqueous extract was prepared with water at 85°C for 20 h, and the ethanol extracts were prepared by refluxing with 50% ethanol or 95% ethanol for 16 h. Then, extract solutions are concentrated by evaporation in vacuo to give the final extract products. The Rb1 and Rg1 levels in the extracts were estimated by liquid chromatography spectrometry using area normalization methods (Figure 1). Following the instructions of the Japanese Pharmacopoeia (<http://jpdn.nihs.go.jp/jp16e/jp16e.pdf>), we estimated the concentration of Rb1 and Rg1. Rb1 and Rg1 were purchased from Abcam Biochemicals (Cambridge, UK). Rb1 and Rg1 were mixed according to the constituents of several commercially available *P. ginseng* extracts. Extracts and ginsenosides were orally administered to mice as a suspension in distilled water (200 μ L).

2.3. Cytotoxicity Assay. Liver and spleen mononuclear cells (MNCs) were prepared as previously described [16–18]. The cytotoxic activity of MNCs was assessed against the NK cell-sensitive YAC-1 cells, using a standard ^{51}Cr release assay [16–18]. Briefly, $\text{Na}_2^{51}\text{CrO}_4$ -labeled YAC-1 cells were coincubated with serial dilutions of MNCs on a round-bottom 96-well plate (Corning Inc., Corning, NY) in 5% CO_2 in air at 37°C for 4 h. Spontaneous release was determined by incubating the target YAC-1 cells in medium, and maximal release was measured by placing the target cells in medium containing 1% Triton X-100. The supernatants were collected to measure radioactivity released during incubation, and the percentage of specific lysis was calculated according to the formula $\text{Specific lysis} = (\text{experimental release} - \text{spontaneous release}) / (\text{maximal release} - \text{spontaneous release}) \times 100$. As the positive control of cytotoxic assay, we concurrently examined the NK cell activity after the intraperitoneal injection of IL-12 (eBioscience, San Diego, CA) and/or IL-28 (R&D Systems, Minneapolis, MN), which has been described to augment NK cell cytotoxic activity [18, 19], using the same target cells at the same cytotoxic assay condition.

2.4. Flow Cytometric Analysis. After preincubation with an anti-mouse CD16/32 (2.4G2) monoclonal antibody (mAb) to reduce nonspecific binding of mAbs to Fc γ receptors, cell surface molecules were stained with FITC-conjugated anti-mouse CD3 mAb (145-2C11) and phycoerythrin-conjugated anti-NK1.1 mAb (PK136) (for B6 mice) or anti-CD49b mAb (DX5) (for BALB/c mice) and analyzed by FACS Caliber (BD

Bioscience, San Jose, CA) [18]. All reagents were purchased from eBioscience.

2.5. Statistical Analysis. Data were analyzed by a two-tailed Student's *t*-test. *P* values less than 0.05 were considered statistically significant.

3. Results

3.1. Augmentation of NK Cell Cytotoxic Activity following Oral Administration of Aqueous *P. ginseng* Extract. Oral administration of 20, 40, or 100 mg/kg aqueous *P. ginseng* extract to WT B6 mice for 2 days augmented the cytotoxicity of liver and spleen MNCs against YAC-1 cells (Figure 2(a)). Administration of 100 mg/kg aqueous *P. ginseng* extract for 1 day also significantly augmented the cytotoxic activity, although 1-day intake of 20 or 40 mg/kg of this extract did not augment cytotoxicity (Figure 2(a)). Neither the overall MNC numbers nor the NK cell populations in the liver and spleen significantly increased (Figure 2(b)). Oral administration of aqueous *P. ginseng* extract (50 mg/kg) augmented liver and spleen NK cell cytotoxicity in BALB/c and B6 mice, suggesting that there was no strain difference in this response (Figure 2(c)). None of the mice treated with oral aqueous *P. ginseng* extract showed signs of hepatotoxicity (assessed by measurement of serum alanine aminotransferase and aspartate aminotransferase) or systemic toxicity (assessed by observation of body weight, gross appearance, and behavior) (data not shown). These results showed that NK cytotoxicity, but not NK cell number, was increased by oral administration of aqueous *P. ginseng* extract.

3.2. Requirement for IFN- γ , but Not for Acquired Immune Cells, for *P. ginseng*-Induced NK Cell Activation In Vivo. To investigate the contribution of acquired immune cells (T cells, NKT cells, and B cells) and IFN- γ on the observed *P. ginseng*-mediated augmentation of cytotoxicity *in vivo*, we orally administered aqueous *P. ginseng* extract (50 mg/kg) to RAG-2 $^{-/-}$ and IFN- $\gamma^{-/-}$ B6 mice. Liver and spleen MNCs showed augmented cytotoxicity when WT and RAG-2 $^{-/-}$ B6 mice received aqueous *P. ginseng* extract (Figure 3(a)). However, this treatment did not elevate the cytotoxicity of liver and spleen MNCs in IFN- $\gamma^{-/-}$ B6 mice (Figure 3(a)), indicating a critical role for IFN- γ in this effect. Neither MNC numbers nor the NK cell populations in the liver or spleen increased, even when cytotoxicity was significantly augmented in RAG-2 $^{-/-}$ B6 mice (Figure 3(b)), consistent with our observations in WT mice. These results indicated that oral administration of aqueous *P. ginseng* extract augmented NK cell cytotoxicity in an IFN- γ -dependent manner that was independent of acquired immune cell responses.

3.3. NK Cell Cytotoxicity Was Not Increased by Rb1 or Rg1. Ginsenosides are the major constituents of *P. ginseng*, and Rb1 and Rg1 are generally considered to be the main effector saponins of the > 20 reported ginsenosides [5]. We examined whether Rb1 and/or Rg1 activated NK activity *in vivo*. WT B6 mice were orally administered with mixtures of Rb1 and Rg1




FIGURE 1: Concentration of Rb1 and Rg1 in aqueous extract, 50% ethanol extract, and 95% ethanol extract. Standard sample was diluted to 0.001%. Each sample was diluted to 0.2%. High-performance liquid chromatography (HPLC) was performed under the following conditions according to the Ginseng section of the revised 16th edition of the Japanese Pharmacopoeia: injected volume, 20 μ L each; detector, UV absorption spectrometer (203 nm); column, stainless, 150 \times 4.6 mm; octadecyl-silica (ODS), 5 μ m. Mobile phase, column temperature, and flow rate for ginsenosides Rb1 and Rg1 were water/acetonitrile (4 : 1) and water/acetonitrile (7 : 3), 30 and 40 degrees Celsius, and retention time of about 25 and 20 minutes, respectively.

that were prepared following analysis of the constituents of several commercially available *P. ginseng* extracts (data not shown). Interestingly, cytotoxic activity was not augmented following oral administration of either Rb1 or Rg1 (Figure 4).

3.4. An Ethanol *P. ginseng* Extract Did Not Augment NK Cell Cytotoxicity. Both alcohol and aqueous extracts of *P. ginseng* are used in complementary and alternative medicines. Our analyses demonstrated that Rb1 and Rg1 were present at





FIGURE 2: Continued.




FIGURE 2: Activation of NK cytotoxicity by oral administration of aqueous *P. ginseng* extract. (a) WT B6 mice ($n = 3$ in each group) were administered with aqueous extract of *P. ginseng* (20 mg/kg; circle, 40 mg/kg; triangle, 100 mg/kg; diamond) on days -2 and -1 (closed symbols) or on day -1 (open symbols). Control mice (open square) ($n = 3$) were administered with the same volume (200 μ L) of water on days -2 and -1. Liver and spleen MNCs were prepared and cytotoxicity was analyzed using NK-sensitive YAC-1 cells, at the indicated effector/target ratios. Data are shown as the mean \pm SD of triplicate samples of all tested mice. Similar results were obtained in three independent experiments. * $P < 0.05$ as compared with the control at each effector/target ratio. (b) The populations of liver and spleen MNCs were analyzed by flow cytometry. MNC numbers and % of NK cells are indicated below every panel. Data are shown as mean \pm SD of three mice in each group. Similar results were obtained in three independent experiments. (c) WT BALB/c and WT B6 mice ($n = 3$ in each group) were administered with aqueous extract of *P. ginseng* (50 mg/kg; closed square) or the same volume (200 μ L) of water (open square) on days -2 and -1. Liver and spleen MNCs were prepared and cytotoxicity was analyzed using YAC-1 cells at the indicated effector/target ratios. Data are shown as mean \pm SD of triplicate samples of all tested mice. Similar results were obtained in three independent experiments. * $P < 0.05$ as compared with the control at each effector/target ratio.

TABLE 1: Rb1 and Rg1 concentrations in the *P. ginseng* extracts.


	Rb1 (%)	Rg1 (%)
Aqueous extract	0.52	0.04
95% ethanol extract	2.66	1.09
50% ethanol extract	1.23	0.50

higher levels in alcohol extracts (Table 1). Thus, we examined the effect of ethanol extracts of *P. ginseng* on NK cell cytotoxicity. Oral administration of the 95% ethanol *P. ginseng* extract to WT B6 did not augment liver or spleen NK cell activity (Figure 5(a)). The 50% ethanol extract appeared to increase cytotoxicity, but this effect was not statistically significant

(Figure 5(a)). Ethanol extract influenced neither the number of MNCs nor the NK cell populations (Figure 5(b)). These results suggested that some constituent that was present at higher levels in the aqueous *P. ginseng* extract augmented NK cell activity *in vivo*.

4. Discussion

In this study, we explored the activation of NK cell cytotoxicity following oral administration of an aqueous *P. ginseng* extract to WT, RAG-2^{-/-}, and IFN- γ ^{-/-} mice. In RAG-2^{-/-} mice, but not in IFN- γ ^{-/-} mice, oral consumption of this extract augmented NK cell cytotoxicity to the same extent as



(a)

FIGURE 3: Continued.




FIGURE 3: IFN- γ -dependent NK cell activation by oral administration of aqueous *P. ginseng* extract. (a) WT, *RAG-2*^{-/-}, or *IFN- γ* ^{-/-} B6 mice ($n = 3$ in each group) were orally administered with aqueous *P. ginseng* extract (50 mg/kg; closed square) or the same volume (200 μ L) of water (open square) on days -2 and -1. Liver and spleen MNCs were prepared and cytotoxicity was analyzed using YAC-1 cells at the indicated effector/target ratios. Data are shown as mean \pm SD of triplicate samples of all tested mice. Similar results were obtained in three independent experiments. * $P < 0.05$ as compared with the control at all effector/target ratios. (b) The populations of liver and spleen MNCs were analyzed by flow cytometry. The MNC number and % of NK cells are indicated below every panel. Data are shown as mean \pm SD of three mice in each group. Similar results were obtained in three independent experiments.

that observed in WT mice. Administration of Rb1, Rg1, or an ethanol extract of *P. ginseng* did not augment NK cell activity. None of the treatments studied affected the MNC or NK cell numbers, even when NK cytotoxicity was augmented. This is the first report to use gene-targeted mice to demonstrate that an aqueous *P. ginseng* extract augmented NK cell cytotoxicity in an IFN- γ -dependent manner.

Extracts of *P. ginseng* are orally ingested as one of the most common complementary medicines for cancers and other diseases, particularly in eastern Asia. The present study therefore used a mouse oral administration model to examine the mechanisms involved in the effects of *P. ginseng* on NK cell activity. *P. ginseng* was reported to augment NK cell activity in rodents and humans [9–13]. Interestingly, consistent with our observations, synergistic increases in the level of serum interleukin- (IL-) 12 and IFN- γ accompanied by NK cell activation [10] and NK cell activation with no substantial effect on T or B cell responses [11] were reported. We hypothesize that *P. ginseng* augments NK cell activity via similar mechanisms in humans and mice.

Epidemiological studies demonstrated an association between ginseng intake and decreased cancer incidence and

growth [20, 21]. Administration of *P. ginseng* has also been reported to inhibit tumor development and/or metastasis, as well as NK cell activation, in mice [9, 22]. The present study demonstrated that oral administration of an aqueous *P. ginseng* extract augmented NK cell cytotoxicity through a mechanism involving IFN- γ . NK cell cytotoxicity and IFN- γ are generally regarded as critical effectors of immune surveillance against tumors [15, 23–25]. It was also reported that *P. ginseng* induced T helper 1 (Th1) and macrophage cytokines, generating lymphokine-activated killer cells in synergy with IL-2 [26]. Thus, cytotoxic immune cells would contribute to the antitumor effects of *P. ginseng*. In addition, ginseng saponins (such as Rg1) have been reported to inhibit the production of inflammatory cytokines, TNF- α and IL-6, [27–30], which are critical for inflammation-related tumor development [31]. Therefore, the antitumor effects of *P. ginseng* would be mediated by both the activation of immune surveillance and inhibition of inflammation-related tumor development.

The results of the present study suggested that some constituent of the aqueous extract, but not of the ethanol extract, augmented NK cell cytotoxicity. Some previous reports




FIGURE 4: Activation of NK cytotoxicity by oral administration of aqueous *P. ginseng* extract, but not by administration of the ginsenosides, Rb1 and Rg1. WT B6 mice ($n = 3$ in each group) were administered with aqueous extract of *P. ginseng* (40 mg/kg), mixtures of the indicated amounts of Rb1 and/or Rg1, or the same volume (200 μ L) of water on days -2 and -1 as indicated. Liver and spleen MNCs were prepared and cytotoxicity was analyzed using YAC-1 cells at the indicated effector/target ratios. Data are shown as mean \pm SD of triplicate samples of all tested mice. Similar results were obtained in three independent experiments. * $P < 0.05$ compared with the control at all effector/target ratios.

have demonstrated that *P. ginseng* had immunosuppressant effects [30, 32, 33]. It was previously reported that monocyte function, monocyte differentiation into dendritic cells, and toll-like receptor-mediated dendritic cell activation were attenuated by *P. ginseng* [30, 33]. Notably, alcohol extracts of *P. ginseng* that contained high levels of the ginsenosides, Rb1 and Rg1, were used in these reports. An acidic polysaccharide from *P. ginseng* was reported to induce regulatory T cells and ameliorate autoimmune disease [34]. It was reported that two different *P. ginseng* extracts had different immunological effects [12]. The effects of various *P. ginseng* extracts probably differ due to their different levels of active compounds.

A variety of receptors, such as toll-like receptors and C-type lectin receptors, have been identified on macrophages, dendritic cells, and innate immune cells [35, 36]. These receptors are thought to mediate sensitivity to microbes, probiotics, and complementary and alternative medicines [37, 38]. The IFN- γ -dependent and acquired immune cell-independent NK cell activation observed following *P. ginseng* administration is fairly similar to that associated with probiotics and β -glucan [17, 39], indicating that toll-like receptors and/or C-type lectin receptors may mediate the effects of *P. ginseng* on

NK cell activation. Moreover, ginsenosides are metabolized by colonic bacteria, and these active metabolites mediate their immune and anticancer effects [18]. Taken together, the range of compounds present in *P. ginseng* extracts, the individual differences in the expression profiles of innate immune receptors in human subjects, and the intestinal bacterial flora would all influence the biological effects of *P. ginseng* in humans. To improve the therapeutic benefits of *P. ginseng*, further studies are required to elucidate the complex molecular mechanisms involved in the biological effects of *P. ginseng*.

Abbreviations

IFN:	Interferon
MNCs:	Mononuclear cells
NK:	Natural killer
RAG-2:	Recombination activating gene 2
WT:	Wild-type
IL:	Interleukin
SD:	Standard deviation.




FIGURE 5: Activation of NK cytotoxicity by oral administration of aqueous, but not ethanol, *P. ginseng* extract. (a) WT B6 mice ($n = 3$ in each group) were administered with aqueous extract (circle), 95% (diamond) or 50% (triangle) ethanol extracts of *P. ginseng* (100 mg/kg), or the same volume (200 μ L) of water (square) on days -2 and -1. Liver and spleen MNCs were prepared and cytotoxicity was analyzed using YAC-1 cells at the indicated effector/target ratios. Data are shown as mean \pm SD of triplicate samples of all tested mice. Similar results were obtained in three independent experiments. * $P < 0.05$ compared with the control at all effector/target ratios. (b) The populations of liver and spleen MNCs were also analyzed by flow cytometry. The MNC number and % of NK cells are indicated below every panel. Data are shown as mean \pm SD of three mice in each group. Similar results were obtained in three independent experiments.

Conflict of Interests

Kazuyoshi Takeda received research funding from Nagaoka & Co., Ltd. Ko Okumura declared no conflict of interests.

Acknowledgments

The authors wish to thank the Mishima Kaiun Memorial Foundation for financial support from a grant in 2004, the Danone Institute of Japan for their financial support of the 2005 DIJ Research Grant, and Nagaoka & Co., Ltd. for their financial support. The authors are grateful to Japan Food Research Laboratories for analyzing the constituents of *P. ginseng* extracts.

References

- [1] H. Abe, S. Arichi, T. Hayashi, and S. Odashima, "Ultrastructural studies of Morris hepatoma cells reversely transformed by ginsenosides," *Experientia*, vol. 35, no. 12, pp. 1647–1649, 1979.
- [2] Y. S. Huang, "Effect of ginsenosides Rb1 and Rg1 on lipid peroxidation of rat in vitro," *Zhongguo yi xue ke xue yuan xue bao*, vol. 11, no. 6, pp. 460–462, 1989.
- [3] X.-B. Sun, T. Matsumoto, H. Kiyohara, M. Hirano, and H. Yamada, "Cytoprotective activity of pectic polysaccharides from the root of *Panax ginseng*," *Journal of Ethnopharmacology*, vol. 31, no. 1, pp. 101–107, 1991.
- [4] M. R. Harkey, G. L. Henderson, M. E. Gershwin, J. S. Stern, and R. M. Hackman, "Variability in commercial ginseng products: an analysis of 25 preparations," *The American Journal of Clinical Nutrition*, vol. 73, no. 6, pp. 1101–1106, 2001.
- [5] T. T. X. Dong, X. M. Cui, Z. H. Song et al., "Chemical assessment of roots of *Panax notoginseng* in China: regional and seasonal variations in its active constituents," *Journal of Agricultural and Food Chemistry*, vol. 51, no. 16, pp. 4617–4623, 2003.
- [6] C. Konno, M. Murakami, Y. Oshima, and H. Hikino, "Isolation and hypoglycemic activity of Panaxans Q, R, S, T AND U, glycans of *Panax ginseng* roots," *Journal of Ethnopharmacology*, vol. 14, no. 1, pp. 69–74, 1985.
- [7] Y.-S. Lee, I. N.-S. Chung, I.-R. Lee, K. I.-H. Kim, W.-S. Hong, and Y.-S. Yun, "Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from *Panax ginseng*," *Anticancer Research*, vol. 17, no. 1, pp. 323–331, 1997.
- [8] D. M. See, N. Broumand, L. Sahl, and J. G. Tilles, "In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients," *Immunopharmacology*, vol. 35, no. 3, pp. 229–235, 1997.
- [9] Y. S. Yun, H. S. Moon, Y. R. Oh, S. K. Jo, Y. J. Kim, and T. K. Yun, "Effect of red ginseng on natural killer cell activity in mice with lung adenoma induced by urethan and benzo(a)pyrene," *Cancer Detection and Prevention*, supplement 1, pp. 301–309, 1987.
- [10] X. F. Du, C. Z. Jiang, C. F. Wu, E. K. Won, and S. Y. Choung, "Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression," *Archives of Pharmacal Research*, vol. 31, no. 9, pp. 1153–1159, 2008.
- [11] J. Y. Kim, D. R. Germolec, and M. I. Luster, "*Panax ginseng* as a potential immunomodulator: studies in mice," *Immunopharmacology and Immunotoxicology*, vol. 12, no. 2, pp. 257–276, 1990.
- [12] F. Scaglione, F. Ferrara, S. Dugnani, M. Falchi, G. Santoro, and F. Frascini, "Immunomodulatory effects of two extracts of *Panax ginseng* C.A. Meyer," *Drugs under Experimental and Clinical Research*, vol. 16, no. 10, pp. 537–542, 1990.
- [13] S. H. Hong, K. T. Suk, S. H. Choi et al., "Anti-oxidant and natural killer cell activity of Korean red ginseng (*Panax ginseng*) and urushiol (*Rhus vernicifera* Stokes) on non-alcoholic fatty liver disease of rat," *Food and Chemical Toxicology*, vol. 55, pp. 586–591, 2013.
- [14] C. A. Biron and L. Brossay, "NK cells and NKT cells in innate defense against viral infections," *Current Opinion in Immunology*, vol. 13, no. 4, pp. 458–464, 2001.
- [15] M. J. Smyth, Y. Hayakawa, K. Takeda, and H. Yagita, "New aspects of natural-killer-cell surveillance and therapy of cancer," *Nature Reviews Cancer*, vol. 2, no. 11, pp. 850–861, 2002.
- [16] K. Takeda, Y. Hayakawa, M. J. Smyth et al., "Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells," *Nature Medicine*, vol. 7, no. 1, pp. 94–100, 2001.
- [17] E. Yuminamochi, T. Koike, K. Takeda, I. Horiuchi, and K. Okumura, "Interleukin-12- and interferon- γ -mediated natural killer cell activation by *Agaricus blazei* Murill," *Immunology*, vol. 121, no. 2, pp. 197–206, 2007.
- [18] W. Hashimoto, K. Takeda, R. Anzai et al., "Cytotoxic NK1.1 Ag α alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12," *Journal of Immunology*, vol. 154, no. 9, pp. 4333–4340, 1995.
- [19] F. Souza-Fonseca-Guimaraes, A. Young, D. Mittal et al., "NK cells require IL-28R for optimal in vivo activity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 112, no. 18, pp. E2376–E2384, 2015.
- [20] Y.-O. Ahn, "Diet and stomach cancer in Korea," *International Journal of Cancer*, supplement 10, pp. 7–9, 1997.
- [21] T.-K. Yun and S.-Y. Choi, "Non-organ specific cancer prevention of ginseng: a prospective study in Korea," *International Journal of Epidemiology*, vol. 27, no. 3, pp. 359–364, 1998.
- [22] H. Hasegawa, R. Suzuki, T. Nagaoka, Y. Tezuka, S. Kadota, and I. Saiki, "Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol," *Biological and Pharmaceutical Bulletin*, vol. 25, no. 7, pp. 861–866, 2002.
- [23] M. F. van den Broek, D. Kägi, F. Ossendorp et al., "Decreased tumor surveillance in perforin-deficient mice," *Journal of Experimental Medicine*, vol. 184, no. 5, pp. 1781–1790, 1996.
- [24] G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, "Cancer immunoediting: from immunosurveillance to tumor escape," *Nature Immunology*, vol. 3, no. 11, pp. 991–998, 2002.
- [25] M. J. Smyth, G. P. Dunn, and R. D. Schreiber, "Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity," *Advances in Immunology*, vol. 90, pp. 1–50, 2006.
- [26] K.-H. Kim, Y.-S. Lee, I.-S. Jung et al., "Acidic polysaccharide from *Panax ginseng*, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2," *Planta Medica*, vol. 64, no. 2, pp. 110–115, 1998.
- [27] A. T. Smolinski and J. J. Pestka, "Modulation of lipopolysaccharide-induced proinflammatory cytokine production in vitro

- and in vivo by the herbal constituents apigenin (chamomile), ginsenoside Rb1 (ginseng) and parthenolide (feverfew)," *Food and Chemical Toxicology*, vol. 41, no. 10, pp. 1381–1390, 2003.
- [28] Y. Wang, B.-X. Wang, T.-H. Liu, M. Minami, T. Nagata, and T. Ikejima, "Metabolism of ginsenoside Rg1 by intestinal bacteria II. Immunological activity of ginsenoside Rg1 and Rh1," *Acta Pharmacologica Sinica*, vol. 21, no. 9, pp. 792–796, 2000.
- [29] C. F. Wu, X. L. Bi, J. Y. Yang et al., "Differential effects of ginsenosides on NO and TNF- α production by LPS-activated N9 microglia," *International Immunopharmacology*, vol. 7, no. 3, pp. 313–320, 2007.
- [30] A. Rhule, B. Rase, J. R. Smith, and D. M. Shepherd, "Toll-like receptor ligand-induced activation of murine DC2.4 cells is attenuated by *Panax notoginseng*," *Journal of Ethnopharmacology*, vol. 116, no. 1, pp. 179–186, 2008.
- [31] M. Karin, "NF- κ B as a critical link between inflammation and cancer," *Cold Spring Harbor Perspectives in Biology*, vol. 1, Article ID a000141, 2009.
- [32] J. M. Lee, J. O. Hah, and H. S. Kim, "The effect of red ginseng extract on inflammatory cytokines after chemotherapy in children," *Journal of Ginseng Research*, vol. 36, no. 4, pp. 383–390, 2012.
- [33] Y. J. Lee, Y. M. Son, M. J. Gu et al., "Ginsenoside fractions regulate the action of monocytes and their differentiation into dendritic cells," *Journal of Ginseng Research*, vol. 39, no. 1, pp. 29–37, 2015.
- [34] I. Hwang, G. Ahn, E. Park, D. Ha, J.-Y. Song, and Y. Jee, "An acidic polysaccharide of *Panax ginseng* ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells," *Immunology Letters*, vol. 138, no. 2, pp. 169–178, 2011.
- [35] K. Takeda, T. Kaisho, and S. Akira, "Toll-like receptors," *Annual Review of Immunology*, vol. 21, pp. 335–376, 2003.
- [36] D. Sancho and C. R. e Sousa, "Signaling by myeloid C-type lectin receptors in immunity and homeostasis," *Annual Review of Immunology*, vol. 30, pp. 491–529, 2012.
- [37] K. Takeda and K. Okumura, "CAM and NK cells," *Evidence-Based Complementary and Alternative Medicine*, vol. 1, no. 1, pp. 17–27, 2004.
- [38] W. Feleszko, J. Jaworska, and E. Hamelmann, "Toll-like receptors—novel targets in allergic airway disease (probiotics, friends and relatives)," *European Journal of Pharmacology*, vol. 533, no. 1–3, pp. 308–318, 2006.
- [39] K. Takeda, T. Suzuki, S.-I. Shimada, K. Shida, M. Nanno, and K. Okumura, "Interleukin-12 is involved in the enhancement of human natural killer cell activity by *Lactobacillus casei* Shirota," *Clinical and Experimental Immunology*, vol. 146, no. 1, pp. 109–115, 2006.